Clinical Trial 49131

Tulsa, OK 74133


The purpose of this Phase III study is to evaluate the efficacy and safety of MEDI3506
300 mg every 8 weeks (Q8W) and 300 mg every 4 weeks (Q4W) dose regimens administered
subcutaneously (SC) in adult participants with symptomatic COPD and history of
≥ 2 moderate or ≥ 1 severe exacerbation of COPD in the previous 12 months. 

  • 40 or older with documented diagnosis of COPD for at least one year 
  • ICS/LABA/LAMA triple therapy, or dual therapy if triple is not indicated or contraindicated) and at a stable dose for at least 3 months 
  • Smoking history of ≥ 10 pack-years (1 pack a day for 10 years or less packs for more than 10 years).
  • Able to read and use electronic devices.


Qualified Participants May Receive:

300 mg of either placebo or IP every 4 weeks. Treatment will be blinded to both subejct and study doctor. After treatment completion, there may be an additional extension for the study and for the patient to continue on treatment. 


Clinical trials are medical research studies designed to test the safety and/or effectiveness of new investigational drugs, devices, or treatments in humans. These studies are conducted worldwide for a range of conditions and illnesses. Learn more about clinical research and participating in a study at About Clinical Trials.